This research roundup discusses researchers’ attempts to find a treatment for a “brain fog” that comes with CAR T-Cell ...

More information: Edgardo Santiago‐Rivera et al, Spider Eye Development Editing and Silk Fiber Engineering Using CRISPR‐Cas, Angewandte Chemie International Edition (2025). DOI: 10.1002/anie.

Every living creature on Earth needs to protect itself from things that would do it harm. Bacteria are no different. And ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

CRISPR Therapeutics recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and diluted loss ...

CRISPR Therapeutics stock is heavily shorted in the weeks going into earnings The short-sellers are betting against the name in a big way, with more than 20 million shares sold short as of the ...

Prasad's social media reveals criticism of Verve's 1st-gen PCSK9 approach, which may signal negative sentiment for CRISPR to navigate. Unlock your all-in-one trading dashboard with real-time ...

acceptphoto via Shutterstock Who’s up for some CRISPR-y bacon? This week, the Food and Drug Administration approved gene-edited pigs developed by PIC, a biotechnology company specializing in ...

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share.